Generic name |
letermovir |
|
---|---|---|
Strength |
240 mg, 480 mg |
|
Form |
tablet |
Special Authority criteria |
Approval period |
---|---|
For the prophylaxis of cytomegalovirus (CMV) infection in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT) AND Who are at high risk of CMV infection meeting the following criteria:
AND Patients must have an undetectable CMV DNA at baseline AND The treatment is prescribed by a specialist physician with the leukemia/bone marrow transplant program |
Maximum coverage is for 100 days per allogeneic HSCT |